The funding will be used by the company to boost its global commercial growth plans and advance ongoing research and development (R&D) activities, in addition to consolidating the clinical development pipeline of its digital therapeutic solutions for a range of neurological diseases
MindMaze offers tech-enabled protocolised software and hardware peripherals to address serious cognitive and movement deficits. (Credit: Raman Oza from Pixabay)
MindMaze has raised $105m in a financing round to advance its digital therapeutic solutions for a range of neurological diseases.
Led by Concord Health Partners, the financing round saw participation from AlbaCore Capital Group, Hambro Perks and several family office investment groups.
The funding will be used by the company to boost its global commercial growth plans and advance ongoing research and development (R&D) activities, in addition to consolidating the clinical development pipeline of its digital therapeutic solutions for a range of neurological diseases.
The latest financing will also help the company to invest in partnerships with pharmaceutical and medical device companies.
It will also enter into a partnership with The American Hospital Association (AHA), as a result of Concord’s investment.
MindMaze founder and CEO Tej Tadi said: “MindMaze has been at the frontier of brain tech since its inception, and we’ve been an essential part of the incredible advancements over the last decade across brain sensing, motion capture, mixed reality platforms, new architectures for brain inspired computing and machine learning/AI.
“We are pleased that important strategic growth investors, such as Concord Health Partners and the larger investment community, see the broad-reaching potential of our digital neurotherapeutics platform as we continue to accelerate humanity’s ability to recover, learn, and adapt.”
MindMaze is focused on the development of tech-enabled protocolised software and hardware peripherals to address serious cognitive and movement deficits.
Its product portfolio consists of three FDA approved products, as well four CE mark products for multiple clinical indications.
The company is anticipating to release minimum three new prescription digital therapeutic solutions for chronic stroke, Parkinson’s disease, and aging/MCI in the next few years.